Krónikus limfoid leukémia (CLL): vizsgálatok itt: Olaszország
46 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Where
- Bergamo, Cuneo, Ferrara, Milan, Naples, Pisa, Ravenna, Rome, Rozzano, Terni
- Életkor
- 18 év and over
- People
- 306 worldwide
- Run by
- Newave Pharmaceutical Inc
See details and how to joinNCT07342478 · EU 2026-525656-28-00 - 3. fázisTaking peopleA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Where
- Alessandria, Milan, Reggio Emilia
- Életkor
- 18 év and over
- People
- 735 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00 - 1. fázisTaking peopleA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Where
- Brescia, Milan, Sant'Andrea Delle Fratte (PG)
- Életkor
- 18 év and over
- People
- 332 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05091424 - 2. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Bari, Ferrara, Florence, Milan, Novara, Padova, Palermo, Perugia, Rome
- Életkor
- 18 év and over
- People
- 249 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01 - 4. fázisTaking peopleA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Alessandria, Florence, Messina, Monza, Perugia, Rome, Terni
- Életkor
- 18 év and over
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218341 - 2. fázisTaking peopleA Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Where
- Alessandria, Bologna, Brescia, Meldola (FC), Milan, Ravenna
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT07221500 - 4. fázisTaking peopleAcalabrutinib Monotherapy vs Investigator’s Choice of Treatment in Patients with Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
- Where
- Cagliari, Florence, Milan, Pavia, Perugia
- Életkor
- 18 év and over
- People
- 33 worldwide
- Run by
- AstraZeneca AB
See details and how to join2023-510147-37-00 · EU 2023-510147-37-00 - 1/2. fázisTaking peopleA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Where
- Bologna, Milan
- Életkor
- 18 év and over
- People
- 408 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00 - 2. fázisTaking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Bari, Bologna, Brescia, Milan, Naples, Pavia, Reggio Emilia, Roma
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - 3. fázisTaking peopleA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Where
- Bari, Cagliari, Catania, Ferrara, Milan, Modena, Pagani
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00 - 2. fázisTaking peopleMAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
- Where
- Meldola, Milan, Padova, Ravenna
- Életkor
- 18 év to 130 év
- People
- 80 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07024706 · EU 2024-518858-17-00 - 3. fázisTaking peopleSingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Brescia, Candiolo, Catania, Florence, Milan, Rome, Varese
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00 - 1/2. fázisTaking peopleSafety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
- Where
- Bologna, Brescia, Genova, Milan, Monza, Naples, Pavia, Rome, Torino
- Életkor
- 1 év to 17 év
- People
- 70 worldwide
- Run by
- Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00 - 1/2. fázisTaking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Bologna, Milan, Roma, Verona
- Életkor
- 18 év and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - 3. fázisTaking peopleA phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
- Where
- Bari, Cagliari, Catania, Milan, Padova, Palermo, Perugia, Rome, Varese
- Életkor
- 18 év and over
- People
- 746 worldwide
- Run by
- University Of Cologne
See details and how to join2023-510294-34-00 · EU 2023-510294-34-00 - 4. fázisTaking peopleRegistry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
- Where
- Bologna, Busto Arsizio, Milan, Modena, Novara, Padova, Perugia, Pescara, Ravenna, Rimini, Rome
- Életkor
- 18 év and over
- People
- 365 worldwide
- Run by
- Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00 - 3. fázisTaking peopleA Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Where
- Meldola, Ravenna, Rome, Tricase
- Életkor
- 18 év and over
- People
- 49 worldwide
- Run by
- Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00 - 1/2. fázisTaking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Bologna, Milan
- Életkor
- 18 év and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - 3. fázisTaking peopleA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Where
- Bari, Florence, Milan, Naples, Novara, Pavia, Perugia, Rome
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06846671 · EU 2024-518893-15-00 - 3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Bologna, Milan, Padova
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - 3. fázisTaking peopleA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Where
- Bologna, Florence, Milan, Padova, Rome
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00 - 4. fázisTaking peopleAcalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
- Where
- Cagliari, Florence, Milan, Pavia, Perugia
- Életkor
- 18 év to 130 év
- People
- 60 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06651970 - 2. fázisTaking peopleA Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a Bcell Lymphoma-2 Inhibitor (BCL-2i) (DAYBreak CLL-201)
- Where
- Alessandria, Bergamo, Bologna, Brescia, Meldola, Milan, Milano, Ravenna, Rome, Turin
- Életkor
- 18 év and over
- People
- 45 worldwide
- Run by
- Nurix Therapeutics Inc.
See details and how to join2025-521088-10-00 · EU 2025-521088-10-00 - No phaseTaking peopleIbrutinib Plus Venetoclax Long-Term Outcomes in CLL
- Where
- Milan
- People
- 323
- Run by
- European Research Initiative on CLL
See details and how to joinNCT07774390 - 3. fázisTaking peopleA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Where
- Alexandria, Bologna, Meldola, Milan, Reggio Emilia
- Életkor
- 18 év and over
- People
- 737 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00